Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04007809
Other study ID # DIATAG
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 15, 2019
Est. completion date June 30, 2027

Study information

Verified date June 2022
Source Université Catholique de Louvain
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of DIATAG study is the identification of biomarkers of T1D evolution in a pediatric cohort.


Description:

Type 1 diabetes (T1D) is a common chronic disease in childhood. Clinical presentation at onset of T1D can vary among patients from long-standing diabetes triad symptoms (polyuria, polydipsia and weight loss) to coma and ketoacidosis. The initial clinical presentation of T1D was shown to have long-term influence on glycemic control of the patient. The investigators initiated a collaborative consortium including six pediatric clinics in Belgium to better characterize new-onset T1D patients. Hypothesis : 1. Different subgroups of T1D patients might exist, underlying different physiopathology of T1D : - The investigators will first investigate the presence of biomarkers in different fluids (e.g. urine, blood, feces,...). - The investigators will correlate results with clinical parameters of glycemic control. Dynamic tests (HOMA and stimulated C peptide) will be realized at 2 defined time points of the follow-up. 2. Glucose variability can be influenced by external factors (e.g. diet, physical activity, Quality of Life (QoL),...) The investigators will evaluate those external factors using approved questionnaires. They will presented to the patient and its parents at 2 defined time points.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 98
Est. completion date June 30, 2027
Est. primary completion date August 15, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Months to 18 Years
Eligibility Inclusion Criteria: 1. Type 1 diabetes de novo according to American Diabetes Association criteria: 1. Polyuria, polydipsia, weight loss ± ketoacidosis 2. Fasting blood glucose =126 mg/dL AND/OR blood glucose =200 mg/dL at the 120th minute of an Oral Glucose Tolerance Test (OGTT) AND/OR HbA1c =6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose =200 mg/dL. 3. Presence in the serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8) 2. Age between 6 months and 18 years. 3. Male or female. 4. Positive for one or more autoantibodies typically associated with Type 1 Diabetes (TD1). 5. Free written and oral consent. Exclusion Criteria: 1. Children under 6 months of age. 2. Treatment that interferes with insulin secretion and insulin sensitivity (e. g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins). 3. Presence of celiac disease (diagnosis based on pathological duodenal biopsy), recently diagnosed (within 1 month), at the time of inclusion. 4. Autoimmune/auto-inflammatory disease (other than type 1 diabetes) or active malignant disease present at inclusion. 5. Obesity defined by a Body Mass Index (BMI) with a z-score >+3 Standard Deviation. 6. Hepatic, renal or adrenal insufficiency. 7. History of spinal cord allograft. 8. History of post-hemolytic-uremic diabetes. 9. Absence of anti-pancreatic islet auto-antibodies. 10. Dysmorphic with suspicion of underlying genetic syndrome. 11. Participation in another study within the previous 3 months, with administration of blood derivatives or potentially immunomodulating treatments.

Study Design


Intervention

Other:
Glucagon
Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).

Locations

Country Name City State
Belgium Cliniques universitaires Saint-Luc Brussels

Sponsors (3)

Lead Sponsor Collaborator
Université Catholique de Louvain BESPEED, Fonds National de la Recherche Scientifique

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of T1D subgroups by using follow-up of clinical parameters : weight in kilograms weight in kilograms up to 18 months after diagnosis
Primary Evaluation of T1D subgroups by using follow-up of clinical parameters : Height in centimeter Height in centimeter up to 18 months after diagnosis
Primary Evaluation of T1D subgroups by using follow-up of clinical parameters : Body mass index (kg/m²) Body mass index (kg/m²) up to 18 months after diagnosis
Primary Evaluation of T1D subgroups by using follow-up of clinical parameters : glycemic variability (%) glycemic variability (%) up to 18 months after diagnosis
Primary Follow-up of laboratory results - glycemia (mg/dL) glycemia (mg/dL) up to 18 months after diagnosis
Primary Follow-up of laboratory results - Insulin (mUI/L) Insulin (mUI/L) up to 18 months after diagnosis
Primary Follow-up of laboratory results - HbA1C (%) HbA1C (%) up to 18 months after diagnosis
Primary Follow-up of laboratory results - C-peptide (mUI/L) C-peptide (mUI/L) up to 18 months after diagnosis
Primary Evaluation and follow-up of diet, physical activity, quality of life using validated questionnaires. Composite of Physical Activity Questionnaire (PAQ), DisabKids, Health Behaviour in School-aged Children (HBSC) up to 18 months after diagnosis
Primary Evaluation and follow-up of physical activity Physical Activity Questionnaire (PAQ). This questionnaire consists of 8 items. Once you have a value from 1 to 5 for each of the 8 items (items 1 to 8) used in the Physical Activity composite score, you simply take the mean of these 8 items, which results in the final PAQ activity summary score.
A score of 1 indicates low physical activity, wheareas a score of 5 indicates high physical activity.
up to 18 months after diagnosis
Primary Evaluation and follow-up of quality of life: DisabKids Questionnaires DisabKids Questionnaires. The paper version of DISABKIDS consisted of the generic health related quality of life questionnaire for 8- to 18-year-olds (37 items) and the DISABKIDS Diabetes module (10 items). The questionnaire is designed to measure health related quality of life of children with a chronic medical condition. Questions are answered on a Likert type scale of 1-5 points. Lower scores correspond to better quality of life. up to 18 months after diagnosis
Secondary Production of prediction model of ß-cell mass evolution Composite score using clinical parameters and laboratory results up to 18 months after diagnosis
See also
  Status Clinical Trial Phase
Completed NCT03886974 - Transition to Adult Care in Type 1 Diabetes
Completed NCT05620251 - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Active, not recruiting NCT05078658 - Low-carbohydrate Diet in Children With Type 1 Diabetes N/A
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT03177096 - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes N/A
Not yet recruiting NCT06418269 - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes N/A
Completed NCT04172077 - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting NCT04950634 - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed NCT04450745 - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients N/A
Completed NCT03165786 - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes N/A
Terminated NCT04028960 - IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase Phase 2
Recruiting NCT05324488 - Diabetes Registry Graz for Biomarker Research
Completed NCT02984709 - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes N/A
Completed NCT02984514 - Brown Adipose Tissue in Type 1 Diabetes N/A
Recruiting NCT06372392 - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps N/A
Recruiting NCT05973799 - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes N/A
Recruiting NCT03311516 - New Insulin Therapy by Multiwave Bolus N/A
Completed NCT03711656 - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques N/A